Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval
The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on data from the Phase 3 HIBISCUS trial showing efficacy and safety results in adolescents and adults living with sickle cell disease1 Sickle cell disease is a...
Covered in this story
Call it yourself
No calls on $MAA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mid-America Apartment Communities →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.